1.9.1 Drugs affecting biliary composition and flow - South & West

All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.

Switch to N&E website

Formulary

Back

1.9 Drugs affecting intestinal secretions Toggle Pages

1.9.1 Drugs affecting biliary composition and flow 1.9.2 Bile acid sequestrants 1.9.4 Pancreatin

Chapter 1: Gastrointestinal Toggle Parent Pages

Irritable bowel syndrome guidance Management of constipation in adults Management of constipation in children Management of diarrhoea in children Management of dyspepsia and gastro-oesophageal reflux disease Paediatric reflux disease guidance Infantile colic guidance 1.1 Dyspepsia and gastro-oesophageal reflux disease 1.2 Antispasmodics and other drugs altering gut motility 1.3 Antisecretory drugs and mucosal protectants 1.4 Antimotility drugs 1.5 Chronic bowel disorders 1.6 Laxatives 1.7 Local preparations for anal and rectal disorders 1.8 Stoma care 1.9 Drugs affecting intestinal secretions

Print this page

Contact us about this page

1.9.1 Drugs affecting biliary composition and flow

First Line

Second Line

Specialist

Hospital Only

Ursodeoxycholic acid

Tablets 150mg, 250mg, 300mg (£18.00 = 60 x 250mg)
Oral suspension sugar free 250mg/5ml (£26.98 = 250ml)

Indications and dose

Dissolution of gallstones
- 8–12mg/kg daily as a single dose at bedtime or in two divided doses, for up to 2 years; treatment is continued for 3–4 months after stones dissolve
Primary biliary cirrhosis
- 12–16mg/kg daily in 3 divided doses for 3 months, then 12–16mg/kg once daily at bedtime

Obeticholic acid

Tablets 5mg, 10mg

Notes

NICE TA443 Obeticholic acid for treating primary biliary cholangitis (April 2017) (NHS England Commissioned)

Odevixibat

Hard capsules 200micrograms, 400micrograms, 600micrograms, 1,200micrograms

Notes

NICE HST17: Odevixibat (Bylvay) is recommended, within its marketing authorisation, as an option for treating progressive familial intrahepatic cholestasis (PFIC) in people 6 months and older (February 2022). It is recommended only if the company provides odevixibat according to the commercial arrangement.